What are the next steps in COVID-19 vaccine development?

COVID-19 vaccine development has entered a new phase. The “race against the clock” era is over, but the science sprint is absolutely not. Today’s challenge is more nuanced: how do we build vaccines that keep up with variants, last longer, work better at blocking infection, and still make sense in real-world clinics, pharmacies, and family decision-making conversations?

In other words, the next steps are less about making a vaccine and more about making a better vaccine systembetter strain matching, better durability, better protection for high-risk groups, better safety monitoring, and better access. Think of it as moving from “emergency engineering” to “smart upgrades.” Same house, stronger wiring.

This article breaks down where COVID-19 vaccines stand now and what comes next in development, using current U.S. public health guidance, FDA updates, NIH and BARDA research priorities, clinical trial pipelines, and professional society recommendations.

Where COVID-19 vaccines stand right now in the U.S.

Before talking about the future, it helps to know the current baseline. In the U.S., the 2025–2026 COVID-19 vaccine strategy is built around a monovalent JN.1-lineage vaccine composition, with the FDA indicating a preference for an LP.8.1 strain match for the 2025–2026 formula. That tells you something important: variant matching is still a core part of vaccine development.

CDC guidance now emphasizes individual-based decision-making (shared clinical decision-making) for many people ages 6 months to 64 years, with stronger risk-benefit emphasis for people at increased risk of severe disease. The CDC also highlights that vaccine recommendations and schedules vary by age, risk, and prior vaccination history.

Several practical updates also show how the product landscape is evolving:

• Moderna’s Spikevax is the only approved COVID-19 vaccine for children ages 6 months–4 years in the current CDC schedule.
• Novavax is included as an option for people ages 12 and older, including a single-dose initial vaccination path in current CDC guidance.
• Moderna’s mNexspike is now part of the approved toolkit for people ages 12 and older.

Translation: the market is no longer “one-size-fits-all,” and future development will continue moving toward targeted products and targeted schedules.

Next step #1: Faster variant matching and smarter strain selection

SARS-CoV-2 is still mutating, and CDC genomic surveillance continues to track variant proportions using sequencing plus model-based estimates. That means vaccine developers can’t treat strain selection as a one-time event; it’s a recurring systems problem.

The FDA’s 2025 VRBPAC process shows the current playbook: evaluate circulating variants, vaccine effectiveness data, human and animal immunogenicity, and manufacturing timelines, then choose a formula that best fits what is circulating (or likely to circulate). This is increasingly similar to seasonal influenza strategybut with faster-moving viral dynamics.

The next development step here is obvious and urgent:

• Shorter lag time between strain selection and rollout
• More flexible manufacturing lines
• Better predictive modeling for which lineages will dominate
• More rapid immunogenicity readouts to support updates

In plain English: by the time a vaccine arrives, we don’t want it to be a “great match for last semester’s exam.”

Next step #2: Broader and longer-lasting protection

One of the biggest reasons next-generation COVID-19 vaccines are needed is durability. CDC public-facing vaccine effectiveness summaries continue to show that protection against hospitalization and urgent care visits declines over time, especially across several months. That’s not a vaccine failure; it’s a sign of the virus, immune biology, and real-world exposure patterns doing what they do.

But it does create a clear R&D target: build vaccines with broader and longer-lasting protection. BARDA’s Project NextGen explicitly identifies that as a focus area, and NIAID has also framed next-generation vaccine goals around enhanced breadth against variants and improved durability.

This is where developers are likely to invest heavily in:

• Antigen design that holds up better across related variants
• Adjuvant strategies that strengthen or extend immune responses
• Dose and formulation optimization to improve response quality
• Platform improvements that make seasonal updating more efficient

The future vaccine may not look dramatically different in your arm, but under the hood, it will increasingly be designed for breadth, persistence, and operational simplicity.

Next step #3: Mucosal vaccines (nasal and oral) to reduce infection and transmission

This is one of the most exciting frontiers in COVID-19 vaccine development. First-generation injected vaccines have been strong at reducing severe illness, hospitalization, and death. But they’ve been less effective at consistently preventing infection and transmission, especially as variants keep changing.

That’s why NIH and Project NextGen have been pushing mucosal vaccine researchvaccines delivered through the nose or mouth, where the virus first enters the body. The idea is simple: if you can generate stronger local immune defenses in the nose, mouth, or upper airway, you may be able to reduce infection and spread more effectively.

NIH has already launched a Phase 1 trial for an investigational nasal COVID-19 vaccine (MPV/S-2P), and the trial design specifically looks at immune responses in both the blood and the nose. That dual readout matters because future vaccine success won’t be judged only by antibody levels in bloodit will also be judged by what happens at the “front door” of infection.

Meanwhile, the clinical pipeline shows this is no longer a niche idea:

• Vaxart has a Phase 2b oral pill COVID-19 vaccine study in the U.S.
• CyanVac’s CVXGA1 intranasal candidate is in Phase 2b testing against an mRNA comparator.
• BARDA-backed efforts are also supporting intranasal candidates through Project NextGen pathways.

If one or more mucosal vaccines can show better prevention of infection or transmission (not just severe disease), that could be a major leap forwardespecially in households, schools, long-term care, and high-contact workplaces.

Next step #4: Correlates of protection and faster, smarter clinical trials

Traditional vaccine efficacy trials are powerful, but they are also slow, expensive, and increasingly difficult to run every season. When the virus keeps changing and public uptake varies, the field needs better shortcutsscientifically valid shortcuts.

That’s where correlates of protection come in: measurable immune signals (like specific antibody patterns) that reliably predict protection against symptomatic COVID-19 or severe disease. If those correlates are validated, they can help developers update vaccines faster using immunobridging studies instead of running giant outcome trials for every tweak.

BARDA’s ecosystem is already investing here. Through the RRPV, a Walgreens-led decentralized retail pharmacy study is designed to assess correlates of protection using humoral immunogenicity data linked to symptomatic COVID-19 outcomes. It uses a real-world retail pharmacy model, which is smart for two reasons:

• It can recruit faster and more broadly than many hospital-only trials.
• It generates evidence in the same settings where millions of people actually get vaccinated.

This is a big deal. The future of COVID-19 vaccine development is not just “new product, new trial.” It’s “new product, better evidence engine.”

Next step #5: Better evidence standards for lower-risk populations

Another major shift is that vaccine development is becoming more segmented by risk group. For older adults and people with higher risk for severe COVID-19, the value proposition remains strong and well-supported by public health and clinical guidance.

For younger, healthier populations, however, regulators and experts increasingly want stronger evidence on the size and duration of benefit. A widely discussed 2025 framework in the New England Journal of Medicine (from FDA leadership) outlined continued update pathways for adults 65+ and other high-risk groups, while emphasizing randomized trial evidence for healthy individuals ages 6 months–64 years who are not at increased risk.

In practical development terms, this means future trials will likely become more targeted, asking sharper questions such as:

• How much symptomatic disease does the updated vaccine prevent in lower-risk groups?
• How long does that protection last?
• Does it reduce transmission in households or schools?
• Which endpoints matter most: infection, urgent care visits, or severe outcomes?

This isn’t a slowdown in science. It’s science getting more specific.

Next step #6: Tailored development for high-risk groups (not just “average adults”)

High-risk groups remain central to COVID-19 vaccine development. CDC guidance makes this clear for older adults and people who are moderately or severely immunocompromised, and the clinical schedules for immunocompromised patients are more specialized than the general schedule.

IDSA’s 2025 guidance for immunocompromised patients reinforces this focus, recommending age-appropriate 2025–2026 COVID-19 vaccination and noting that a second dose is likely to extend protection. IDSA also supports coadministration with influenza and RSV vaccinesan operational point that matters a lot in real clinics.

Development-wise, “tailored” means:

• Studying dose timing and spacing for immunocompromised groups
• Evaluating vaccine performance in people with transplants, cancer, and immune-modifying therapies
• Designing trials and labels that reflect risk-specific realities
• Testing coadministration strategies during respiratory virus season

It also means preserving evidence-based guidance for pregnancy and pediatrics. CDC continues to identify pregnancy as a condition where vaccination offers strong benefit, and major U.S. professional groups such as ACOG and AAP continue to publish COVID-19 vaccination guidance relevant to pregnant people and children. Future vaccine development has to support these groups with clear safety, immunogenicity, and effectiveness datanot vague assumptions.

Next step #7: Stronger safety monitoring and clearer risk communication

If next-generation vaccines are going to succeed, they need more than good trial data. They need trust. And trust is built through transparent, ongoing safety monitoring.

CDC and FDA both continue to run active and passive vaccine safety surveillance systems, including collaboration across multiple health data networks. CDC emphasizes that COVID-19 vaccines underwent the most intensive safety monitoring in U.S. history, and FDA’s CBER describes a surveillance framework that can detect and refine safety signalsincluding in specific subpopulations.

The FDA’s 2025 label warning update on myocarditis and pericarditis is a good example of how this should work: continue monitoring, publish what is known, update labels, and keep studying outcomes. That kind of transparency doesn’t weaken vaccine developmentit strengthens it.

Future vaccine development will need safety plans baked in from day one, including:

• Longer follow-up in post-approval studies
• Subpopulation analyses (adolescents, young adults, immunocompromised, pregnancy)
• Clearer communication around rare adverse events and benefits
• Public dashboards and regular updates people can actually understand

Next step #8: Build the delivery infrastructure while building the science

Vaccine development is not just a lab problem. It is a logistics problem, a pharmacy problem, a reimbursement problem, and a “Can people actually get this easily?” problem.

BARDA’s Project NextGen and related infrastructure programs reflect that reality by combining product development with deployment thinkingclinical trials in retail settings, public-private partnerships, and flexible program areas for vaccines, therapeutics, and enabling technologies.

This matters because the next-generation vaccine that wins in practice may not be the one with the flashiest press release. It may be the one that:

• Can be manufactured quickly after strain selection
• Ships broadly before respiratory season peaks
• Fits pharmacy workflows
• Has clear age/risk guidance
• Works well alongside flu and RSV vaccination visits

In short: the future is not only about immunology. It’s about making the whole vaccination system less fragile.

What this means for the future of COVID-19 vaccine development

The next era of COVID-19 vaccine development will likely be defined by a combination of incremental and breakthrough progress:

• Incremental: better strain matching, refined schedules, stronger evidence standards, improved safety monitoring.
• Breakthrough: mucosal vaccines, validated correlates of protection, and broader pan-coronavirus protection.

If all of that sounds like a lot, that’s because it is. But this is how mature vaccine development works. First-generation vaccines saved lives at scale. Next-generation vaccines are being built to improve durability, reduce transmission, and fit the realities of a virus that keeps evolving.

The goal is no longer just “a shot.” The goal is a smarter, faster, more resilient vaccine ecosystem that can respond to COVID-19 now and help prepare for the next coronavirus threat, too.

Experience-based insights: what researchers, clinics, and families are learning (500-word add-on)

One of the most useful ways to understand the next steps in COVID-19 vaccine development is to look at what people on the ground are experiencing right now. Not just in research centers, but in pediatric offices, oncology clinics, pharmacies, and regular family conversations where somebody eventually asks, “Okay, but do I actually need this this year?”

In clinics, the biggest experience shift is that COVID-19 vaccine conversations now sound more like shared decision-making than one-size-fits-all messaging. A healthy 28-year-old, a pregnant patient, a 70-year-old with diabetes, and a teenager on immune-suppressing medication may all get different advice windows, timing recommendations, or follow-up plans. That doesn’t mean the science is weakerit means the science is becoming more personalized. In practice, clinicians need better tools: cleaner dosing tables, clearer risk categories, and product labels that are easier to apply during a busy appointment.

Pharmacies are also teaching the field an important lesson: convenience is part of effectiveness. A vaccine can be scientifically excellent and still underperform if people can’t access it quickly. That’s why decentralized studies in retail settings are so interesting. They mirror real life. People do not schedule their lives around ideal trial conditions; they show up after work, with a sick kid, while trying to remember whether they got their flu shot already. If future vaccine development can prove safety, immunogenicity, and protection in those settings, the evidence becomes much more practical.

Researchers, meanwhile, are experiencing a different challenge: speed versus certainty. Variant updates require rapid decisions, but durable evidence takes time. This is where correlates of protection could change everything. Scientists have long known that waiting for every seasonal update to generate giant outcome trials is not always realistic. The field’s experience has made it clear that better immune markersones that reliably predict protectioncould help vaccines evolve faster without sacrificing scientific rigor. It’s the difference between flying blind and flying with instruments.

Families and caregivers bring another real-world lesson: communication fatigue is real. Many people are not anti-science; they are just overwhelmed by changing guidance, product names, and eligibility rules. They hear “updated vaccine,” “booster,” “formulation,” “shared decision-making,” and their brain politely exits the chat. Future vaccine development will need communication strategies as much as lab advances. If a nasal vaccine becomes available, for example, uptake may depend as much on how well its benefits are explained (infection reduction, easier administration, less needle anxiety) as on the immunology itself.

Finally, there’s a practical experience researchers and public health teams keep repeating: COVID-19 does not behave like a once-a-year problem. It circulates year-round, with seasonal waves and variant shifts. That lived reality is pushing vaccine development away from “annual update only” thinking and toward more flexible timing, more adaptive trial design, and better surveillance integration. In that sense, the biggest experience-based takeaway is simple: the future of COVID-19 vaccination is not a single breakthrough product. It’s a smarter system that learns continuouslyand gets easier for real people to use.

Conclusion

So, what are the next steps in COVID-19 vaccine development? In one sentence: better matching, broader protection, longer durability, stronger evidence, smarter trials, and more practical delivery. The science is moving beyond emergency response and into optimization mode.

The most promising advances include mucosal vaccines (nasal and oral), pan-coronavirus candidates, correlates of protection for faster updates, and risk-based vaccine strategies that protect the people who need protection most. Just as important, U.S. agencies and clinical groups continue building the safety and monitoring systems needed to support public trust.

COVID-19 vaccine development is no longer just about reacting to the virus. It’s about staying one step ahead of itand, ideally, a few steps ahead of the next one.